Clinical trials: Acute Phase
Migraine
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo.
- Trial name
- AT-06 (NCT05685225)
- Testing
- Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen
- Where
- United States
- Sponsor
- Allodynic Therapeutics, Inc
Leukemia
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.
- Trial name
- NCT00405054
- Testing
- MK0457
- Volunteers
- 52 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Tract Infections
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
Multi-center, randomized, double-blind, non-inferiority study of cefepime 2 g/AAI101 500 mg combination compared to piperacillin 4 g/tazobactam 500 mg in a population of adult patients with cUTI or AP.
- Trial name
- NCT03687255
- Testing
- cefepime/AAI101 combination, Piperacillin/tazobactam
- Where
- 24 sites in United States, Argentina and 17 more
- Volunteers
- 1,043 people
- Sponsor
- Allecra
Acute Ischemic Stroke
DS1040b/Aspirin Drug/Drug Interaction Study
This is a phase 1, open label, single dose study, after 5 days of aspirin treatment, in healthy male and female subjects. It is hypothesized that co-administering DS-1040b with aspirin at steady state will be safe and well…
- Trial name
- NCT02071004
- Testing
- DS-1040b, Aspirin
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA
Acute Myelogenous Leukemia
Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
The purpose of this study is to establish the maximum tolerated dose (MTD), and to assess the safety and tolerability of MLN4924 (pevonedistat) in combination with azacitidine in treatment naive participants with AML who were 60…
- Trial name
- NCT01814826
- Testing
- MLN4924, Azacitidine
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Leukemia, Myeloid, Acute
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse
Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse…
- Trial name
- NCT01690624
- Testing
- BI 836858
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia, AML
- Trial name
- NCT00964873
- Testing
- STA-9090 (ganetespib)
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Synta Pharmaceuticals Corp.
cKIT-positive Solid Tumors, AML
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/κ antibody conjugated to a maytansine payload via a non-cleavable linker. LOP628 provides an opportunity to target cKit overexpressing tumors.
- Trial name
- NCT02221505
- Testing
- LOP628
- Where
- 4 sites in Australia, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Abdominoplasty
Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain
Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in patients after mini-abdominoplasty
- Trial name
- NCT04182880
- Testing
- CPL-01
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cali Pharmaceuticals LLC
Covid19, SARS (Severe Acute Respiratory Syndrome)
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
The study is a double-blind, randomized, placebo-controlled, multi-center, Phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
- Trial name
- NCT04629703
- Testing
- Fostamatinib
- Where
- 47 sites in United States, Argentina and 2 more
- Volunteers
- 280 people
- Sponsor
- Rigel Pharmaceuticals
Pain
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
Primary Objective： To explore the analgesic efficacy of YZJ-4729 compared with placebo in patients with acute postoperative pain following abdominal surgery.
- Trial name
- NCT06680466
- Testing
- YZJ-4729, morphine
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Acute Respiratory Distress Syndrome, Adult
Add-on Reparixin in Adult Patients With ARDS
Study objectives 1. To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to…
- Trial name
- NCT05496868
- Testing
- Reparixin 600mg
- Where
- 40 sites in United States, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Dompé Farmaceutici S.p.A
AML, Acute Myeloid Leukemia
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid…
- Conditions
- AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- CertainT-1 (NCT06834282)
- Testing
- CER-1236, Cyclophosphamide, Fludarabine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- CERo Therapeutics Holdings, Inc.
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
The main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with…
- Trial name
- AUDAX (NCT07223190)
- Testing
- Blinatumomab, HyperCVAD
- Volunteers
- 560 people
- Sponsor
- Amgen
Acute Leukemia, Chronic Myeloproliferative Disease
A Phase I Trial of ZIO-101 in Hematologic Cancers
This study uses a new investigational (not yet approved by the FDA for widespread use) drug called ZIO-101, an organic arsenical.
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma
- Trial name
- NCT00592046
- Testing
- ZIO-101 (Darinaparsin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Myelogenous Leukemia, Acute
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and efficacy of RO5045337 in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01635296
- Testing
- RO5045377, cytarabine
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Bipolar Disorder
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
Bipolar disorder is characterized by mood swings that range from high (manic) to low (depressed) states. Sometimes, symptoms of both depression and mania are present (mixed episodes).
- Trial name
- NCT00159796
- Testing
- Asenapine, Olanzapine
- Volunteers
- 489 people
- Sponsor
- Organon and Co
Intracerebral Hemorrhage, Brain Hemorrhage
PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
The purpose of this prospective, single center, single arm registry is to assess technical feasibility, peri-procedural complications, post-procedure imaging outcomes, and 30-day safety outcomes in subjects with intraventricular…
- Conditions
- Intracerebral Hemorrhage, Brain Hemorrhage, Intraventricular Hemorrhage
- Trial name
- PRONTO (NCT04178746)
- Testing
- Artemis Neuro Evacuation Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Penumbra Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.